Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan

This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.